| 2.02 -0.01 (-0.49%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.85 |
1-year : | 3.22 |
| Resists | First : | 2.44 |
Second : | 2.75 |
| Pivot price | 2.11 |
|||
| Supports | First : | 1.94 |
Second : | 1.61 |
| MAs | MA(5) : | 2.01 |
MA(20) : | 2.15 |
| MA(100) : | 2.89 |
MA(250) : | 4.62 |
|
| MACD | MACD : | -0.2  |
Signal : | -0.2 |
| %K %D | K(14,3) : | 10.9 |
D(3) : | 9.7 |
| RSI | RSI(14): 27.8 |
|||
| 52-week | High : | 17.47 | Low : | 1.94 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IMNN ] has closed above bottom band by 24.9%. Bollinger Bands are 27.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.16 - 2.17 | 2.17 - 2.17 |
| Low: | 1.91 - 1.93 | 1.93 - 1.94 |
| Close: | 2 - 2.02 | 2.02 - 2.04 |
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
Tue, 09 Jun 2026
Imunon (IMNN) chair receives stock grant and updates IRA holdings - Stock Titan
Tue, 09 Jun 2026
Imunon (IMNN) CEO Stacy Lindborg granted 1,593 shares as salary stock - Stock Titan
Thu, 04 Jun 2026
IMUNON Secures Up to $10 Million Financing to Advance Phase 3 Ovarian Cancer Trial - citybiz
Thu, 04 Jun 2026
Imunon Secures $10 Million Financing From Streeterville Capital; Issues Preferred Stock and Notes - TradingView
Thu, 04 Jun 2026
IMUNON Announces Up to $10 Million Cash Financing - GlobeNewswire
Thu, 04 Jun 2026
Imunon Secures $10 Million Funding Package to Advance Phase 3 Ovarian Cancer Study (IMNN) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 11.9 (%) |
| Shares Short | 147 (K) |
| Shares Short P.Month | 142 (K) |
| EPS | -4.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -124.5 % |
| Return on Equity (ttm) | -768.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.45 |
| PEG Ratio | 5 |
| Price to Book value | 3.01 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|